Ignite Creation Date:
2024-05-05 @ 9:14 PM
Last Modification Date:
2024-10-26 @ 10:01 AM
Study NCT ID:
NCT00847015
Status:
COMPLETED
Last Update Posted:
2016-02-29
First Post:
2009-02-18
Brief Title:
Gemcitabine Cisplatin and Sunitinib GC-S as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II Study of Gemcitabine Cisplatin and Sunitinib GC-S as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out if using the combination of standard chemotherapy gemcitabine and cisplatin plus this new targeted pill sunitinib can help shrink your tumor before you undergo surgery for your bladder cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None